Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

Blackstone commits $750 million to J&J phase 3 eye-disease research

Blackstone will provide $750 million for J&J’s OLN324 Phase 3 program, subject to the Ollin acquisition closing.

Published 17 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

Blackstone Life Sciences announced on November 16, 2026, that its managed funds will provide $750 million to Johnson & Johnson for Phase 3 development of OLN324, conditional on J&J completing its acquisition of Ollin Biosciences. The agreement commits private capital to a named clinical research program while J&J brings the development and commercial capabilities.

A financing agreement alongside the Ollin acquisition

The commitment accompanied J&J’s agreement to buy Ollin for $2.2 billion upfront, with potential additional payments to the biotech’s shareholders. The two transactions serve different purposes: the acquisition brings Ollin into J&J, while the Blackstone arrangement finances the late-stage research program. BioSpace’s reporting identifies the acquisition’s completion as the point on which the development funding depends.

Blackstone’s money will go to J&J over several years. In exchange, the investor becomes eligible for regulatory and sales milestone payments and single-digit royalties. That structure gives Blackstone a return tied to subsequent program and commercial outcomes. It is a negotiated corporate financing arrangement, with J&J as the recipient, rather than an open research grant competition.

How the payments fit together

The financial terms published by J&J separate the purchase consideration from the development commitment and the investor’s potential returns. Keeping those flows separate matters when assessing how much capital actually supports the Phase 3 trial program.

Payment Announced terms Purpose
Ollin acquisition upfront payment $2.2 billion from J&J Purchase of Ollin
Additional acquisition consideration Up to approximately $1.125 billion Regulatory and commercial milestones
Blackstone development funding $750 million over multiple years Fully fund OLN324 Phase 3 development
Blackstone’s potential returns Regulatory and sales milestones plus single-digit royalties Consideration for providing development capital

The acquisition milestones and Blackstone’s milestone payments belong to different agreements. The former increase what J&J may pay for Ollin; the latter compensate its financing partner. Adding all the headline figures together would therefore misstate the research funding commitment.

J&J brings the program capabilities

Dow Jones reported that the transaction expands an ophthalmology business already spanning surgical vision, contact lenses and ocular surface care. The acquisition would add Ollin’s lead investigational asset to that business. For readers following ophthalmology research, the development is a combination of a pharmaceutical buyer and a specialist capital provider around one late-stage program.

J&J’s announcement places its scientific, development and commercial capabilities behind advancing OLN324. Blackstone’s announcement defines its contribution as financing the clinical program following the expected acquisition close. Those are the responsibilities described in the announcements: a company acquiring and advancing the asset, supported by a private investment platform supplying development capital.

Private capital is supporting other pharmaceutical programs

The agreement follows another large Blackstone commitment announced five days earlier. On November 11, Pfizer and Blackstone announced funding of up to $1.5 billion in development costs through 2028 for Pfizer’s berobenatide program. Blackstone’s potential compensation in that arrangement is also linked to specified milestones.

Pfizer explicitly said it retains operational control and decision-making, and that Blackstone acquires no rights or ownership in berobenatide. Those provisions describe Pfizer’s agreement. They illustrate why the amount of financing and the allocation of program authority are separate parts of a development deal, each requiring attention to the specific terms.

In the Pfizer announcement, chief financial officer Cecile Guegan described external investment as complementing internal research spending while preserving capacity to invest across the wider pipeline. Pfizer also said any earned milestone payments to Blackstone would be payable over multiple years, and that Blackstone’s perpetual private equity strategy would invest alongside its life sciences funds. The earlier agreement therefore offers a concrete example of both funding and potential returns extending across several years.

Fierce Biotech framed the J&J arrangement as a way to advance OLN324 through late-stage development without adding to J&J’s R&D budget. The research-finance significance is the use of external capital to support a particular program alongside a corporate acquisition.

Blackstone emphasises scale and strategic opportunities

In Blackstone’s announcement, global head Nicholas Galakatos said the financing demonstrates the firm’s capacity to provide capital at scale for pharmaceutical companies pursuing strategic opportunities. He also described the transaction as an expansion of its relationship with J&J.

That rationale concerns how research is financed and brought into a larger development organisation. The announced investment is directed to clinical advancement, and the company statements describe OLN324 as investigational.

What research offices can take from the deal

For research administrators tracking funding, the practical reading of these terms is to distinguish committed program capital from acquisition spending and contingent payments. The recipient, research stage, multi-year payment structure and closing condition define the scope of this commitment. University grant budgets should not count the acquisition price as available research support.

Closing is expected before the end of 2026

J&J expects the acquisition to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions. The Blackstone agreement depends on that closing. J&J also said it would communicate the accounting treatment on or before the transaction closes.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →